This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This is about estimating your near-term risk of a heartattack. In this scenario, your risk of a heartattack over the next 10 years is well under 2%. In this case, going on a statin or any other LDL cholesterol-lowering medication will reduce your risk of a heartattack by about 25%. Not zero risk.
Atherosclerotic cardiovasculardisease (ASCVD), caused by plaque buildup in arterial walls, is one of the leading causes of disability and death worldwide.1,2 1,2 ASCVD causes or contributes to conditions that include coronary artery disease (CAD), cerebrovascular disease, and peripheral vascular disease (inclusive of aortic aneurysm).3
The answer is pretty simple, but most people get this wrong, and doing so increases their future risk of heartattack and strokes. We need to do better if we want to majorly impact rates of cardiovasculardisease worldwide. Outcome over process, in my view, works best here. There are others also. Nat Rev Nephrol.
Its effects on the heart are particularly alarming, as smoking significantly increases the risk of cardiovasculardiseases (CVDs) and complicates medical procedures such as minimally invasive or bloodless heart surgeries.
This refers to all the steps necessary to reduce the odds of a subsequent event, such as a second heartattack or stroke. So, let’s cover seven things that reduce the risk of a subsequent heartattack. Just because you have heartdisease or have had a heartattack does not mean there is a lot that can be done.
Caristo Diagnostics Limited has announced the results of a landmark clinical study published in The Lancet that support the ability of Caristo's CaRi-Heart AI technology to quantify coronary artery inflammation and accurately predict cardiac events. Coronary inflammation is a crucial piece of the puzzle in predicting heartattack risk.
Imagine a future where a silent, undetected heart condition is caught before it turns into a life-threatening event a future where artificial intelligence (AI) -powered insights alert clinicians to warning signs long before symptoms appear. Cardiovasculardisease (CVD) remains the leading cause of death in the U.S.
Eighty percent of heartattacks and strokes are preventable. partially because its key risk factor, high blood pressure, is a ‘silent killer,’ and most patients have no symptoms before their first heartattack or stroke. Yet, CVD remains the leading cause of death in the U.S.,
With this new funding, Cleerly will continue to scale its commercial growth and clinical evidence generation, helping health care professionals improve outcomes for patients across the coronary care pathway. Barclay continued, “Cardiovasculardisease is the #1 cause of death globally and costs our country $422B annually.
A projected rise in heartdisease and stroke – along with several key risk factors, including high blood pressure and obesity – is likely to triple related costs to $1.8 population could be affected by cardiovasculardisease within the next 30 years, according to two new science reports. and Susan F. to 61% of the U.S.
The study evaluated the ability of the Fat Attenuation Index (FAI) Score on routine CCTA to predict cardiovascularoutcomes in different socioeconomic classes, ethnicity groups, and in the presence or absence of obstructive coronary artery disease (CAD).
Within the complex umbrella of cardiovasculardisease, CAD is a type of heartdisease that develops when the coronary arteries narrow and the heart cannot deliver enough oxygen-rich blood to the heart. Accessed May 2024. Kirtane, Yongjian Wu, William Wijns, Weixian Yang, Martin B. Leon, Shubin Qiao, Gregg W.
Zerlasiran is a siRNA (short interfering RNA) designed to lower the body’s production of Lp(a), a key genetic risk factor for cardiovasculardisease affecting up to 20% of the world’s population. Median percentage reduction in Lp(a) of 90% or greater were observed for both doses at week 36.
While the typical image of someone suffering a heartattack might be a man clutching his chest, heartdisease is a major problem for women, too. In fact, it's the leading cause of death among women in the United States, with nearly 45% of the nation's women over age 20 living with some form of cardiovasculardisease.
adults—and more than 2 in 5 adults aged 60 years and older—have elevated triglycerides, also known as hypertriglyceridemia , putting them at an increased risk for heartattacks and stroke. milla1cf Sun, 04/07/2024 - 18:20 April 7, 2024 — An estimated 1 in 5 U.S. and Canada. Patients’ median triglyceride level was 242 mg/dL.
Food and Drug Administration (FDA) for its PlaqueIQ imaging analysis software to help physicians diagnose cardiovasculardisease (CVD). I believe plaque quantification has the potential to greatly improve outcomes for patients while providing tremendous savings to the healthcare system.”
“Our findings show that interventions based on techniques from behavioral economics can achieve and sustain increased levels of physical activity in a population with risk factors for cardiovasculardisease and could be another tool to help reduce cardiovascular risk.”
Introduction: Addressing the Need for Improved LDL Management in the US There is a clear need for innovative treatments to combat cardiovasculardisease (CVD). Heartdisease remains the leading cause of death for men and women. However, every 40 seconds, an individual in the US suffers a heartattack.
milla1cf Sun, 04/07/2024 - 18:09 April 7, 2024 — Among patients at high or very high risk for a heartattack or stroke, the addition of the investigational drug lerodalcibep to standard cholesterol-lowering medication for one year reduced LDL, or “bad” cholesterol, levels by more than half on average, compared with a placebo.
But What About Stress & HeartDisease? When stress is included in the risk factor profile for a future heartattack, it comes in third on the list after abnormal cholesterol and smoking 1. Regardless of what is driving the effect, it is clear that experiencing high levels of stress is associated with worse outcomes.
A new joint guideline from the American Heart Association (AHA), the American College of Cardiology (ACC) and nine other medical societies reports early diagnosis and treatment of peripheral artery disease is essential to improve outcomes and reduce amputation risk, heartattack, stroke and death for people with Peripheral Artery Disease (PAD).
Exercise prevents and reverses cardiovasculardisease, but whether high-intensity exercise training (HIIT) is safe and effective for adults after minimally invasive heart surgery is unknown. Exercise is a wonder drug for cardiovasculardisease (CVD) prevention and reversal. Cardiac rehab works wonders.
Rather than just aiming to get ‘Healthy’ this year, how about setting clear targets for improvement that are highly correlated to positive health outcomes? ApoB The relationship of serum ApoB levels and cardiovascular risk over your lifetime is clear. Subscribe now V02 Max. Subscribe now The inverse then holds true.
Objective Assessment of generalisability of guideline-informing trials on antithrombotic treatment intensification to real-world patients with cardiovasculardisease (CVD).
The highly positive outcomes observed in primate models highlight the potential of this strategy. Cardiovasculardiseases are still among the top causes of death worldwide, and especially prevalent in developed countries. Heartattacks typically kill millions of cardiac muscle cells, leaving the heart in a weakened state.
Aims:Asian Americans experience disproportionate burdens of cardiovascular risk factors and cardiovasculardisease (CVD). However, the trends in cardiovascular risks in adults from different Asian ethnic backgrounds remain understudied. Circulation, Volume 150, Issue Suppl_1 , Page A4140513-A4140513, November 12, 2024.
The study aims to evaluate the applicability in the real world of randomised clinical trials (RCT) on antithrombotic treatment in patients with cardiovasculardisease (CVD) and peripheral artery disease (PAD).
The opportunity is even greater in millions of lung CT scans,” said Dr. Morteza Naghavi, founder and president of HeartLung Technologies, and founder of nonprofit SHAPE (Society for HeartAttack Prevention and Eradication). This unique aspect makes AutoChamber a cost and time-saving solution for physicians and healthcare system.
Obesity is also a key driver of risk for cardiovasculardisease. Poor Sleep Increases The Rate Of HeartAttacks & Stroke. Shortened sleep is now recognised as part of the eight key factors of good cardiovascular health. Poor Sleep Increases The Rate Of HeartAttacks & Stroke.
Below, we aim to debunk common myths about cardiovasculardisease, providing accurate information and emphasizing the importance of treatment for heartdisease with timely interventions. It’s crucial to recognize heart health is a lifelong endeavor and preventive measures should begin early.
Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovasculardisease.
2, 2024 — Eko Health recently announced a new independent study from researchers at Imperial College London (Imperial) that demonstrated how AI can identify patients with significantly higher risk of experiencing major adverse cardiac events (MACE), including heartattacks and heart failure. Nicholas S.
Understanding CardiovascularDisease in Women Understanding cardiovasculardisease in women involves recognizing unique risk factors such as hormonal changes and pregnancy-related complications, necessitating proactive care and awareness to manage and prevent heartdisease effectively.
Share Let’s first state our goal when we are in the business of ‘HeartDisease Prevention’: To delay the onset of coronary artery disease (atherosclerosis/plaque) that might rupture and cause a heartattack. And the less plaque you have, the lower the risk of a heartattack.
A clearer view of the arterial system enables healthcare professionals to identify and address issues more effectively, contributing to improved patient outcomes. Timely imaging enables the early identification of cardiac conditions, paving the way for proactive intervention and ultimately resulting in improved patient outcomes.
While I have covered many of these fitness measures individually in previous posts, I wanted to summarise these metrics and how they relate to living longer and preventing major diseases such as cardiovasculardisease, cancer and dementia. Let’s start with the most basic measures and then examine increasingly complex ones.
The study, “Comprehensive Cardiovascular Risk Factor Control with a Mobile Health Cardiovascular Risk Self-Management Program,” highlights the potential use of digital health technology in the comprehensive control of risk factors for cardiovasculardisease (CVD), the leading cause of death and disability in the United States.
IVL is a minimally invasive, catheter-based treatment for calcified arterial lesions, which can reduce blood flow and cause pain or heartattack. Shockwave is a leading, first-to-market provider of innovative intravascular lithotripsy (IVL) technology for the treatment of calcified CAD and PAD.
20th October 2023 (With lessons from, and for, all other health services around the world) The Quality and Outcomes Framework The Quality and Outcomes Framework (QOF) was to be the glittering triumph of Evidence Based Medicine. Many of the commonest and most deadly diseases afflicting humanity would be picked up early, then treated.
I do this for three reasons: There is a relationship between short sleep and worse cardiovascularoutcomes. Poor sleep generally impacts cognitive well-being, nutrition and exercise routines, all of which are key pillars of cardiovascular health. Prevalence estimates of sleep apnea in several cardiovascular conditions.
Among numerous other disorders, patients suffering from cardiovasculardiseases have the largest mortality rate. Where developing countries have somehow managed to provide treatment for their citizens suffering from cardiovasculardiseases. The surge for patients requiring cardiovascular care is enormous.
Doubling this amount to 300 minutes of moderate-intensity or 150 minutes of vigorous-intensity activity per week would (if adhered to, of course) yield massive benefits for cardiovascular health. Remember that cardiovasculardisease is the leading cause of death around the world. Something’s gotta give.
Share JUPITER In 2008 a landmark paper was published showing that in people without cardiovasculardisease and relatively normal LDL-cholesterol (<3.4 mmol/l or 130 mg/dl), the use of rosuvastatin 20mg significantly reduced the likelihood of major cardiovascular events 1. Circ Cardiovasc Qual Outcomes. What To Do?
Randomised outcome-based trials will be necessary to assess whether lowering Lp(a) levels with such an approach will translate into meaningful clinical benefits, i.e. fewer heartattacks. Our options are limited for reducing the excess risk of early cardiovasculardisease as a consequence of elevated Lp(a) levels.
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content